Nanochon Turns 10
Dear Colleagues, Nanochon’s 10-year anniversary represents a time for us to reflect on the immense progress we’ve made over the […]
News
News
2026 First Quarter Update
CAPITAL Following the formal close of our Seed Prime II round at $4.1M (pre-money valuation: $24M) announced in January, additional
Abstract
Nanochon Abstract Presented at AAOS 2026
Charlotte K Barton1, Kathryn Seabaugh 1, Ben Gadomski 2, Kevin Labus 2, Ben Holmes 3, Nathan Castro 3, Mike Hawes
News
2025 Fourth Quarter Update
Capital Nanochon has closed another oversubscribed round, bringing in new capital and increasing the total amount raised to $4.1M. This
News
UVAToday Features Nanochon
This article was originally published on UVA Today This Alum’s Tech May Revolutionize Knee Joint Replacements Benjamin Holmes can pinpoint
Press Release
Nanochon closes $4.1M Seed Prime II Funding Round
WASHINGTON, January 12, 2026 — Nanochon, a Washington, DC-based orthopedic device company developing an implant for treating articular cartilage defects
Abstract
Cadaveric Evaluation of Three Novel Cartilage Repair Implants
Emilia Aram , David C. Flanigan, MD, Nathan J. Castro, PhD, Doug Snell, Luke Aram Purpose: Osteochondral defects can present
Abstract
Treatment of full thickness cartilage lesions with a 3D Printed Nanochon Implant in an Equine model
Charlotte K Barton BVSc, MS, DACVS-LA, MS, MS, Katie A Seabaugh DVM, MS, DACVS-LA, DACVSMR, Ben Gadomski BS, PhD, Kevin
News
2025 Third Quarter Update
Nanochon has secured commitments to close oversubscribed convertible note, bringing our total capital raised to date to $11.3 million. While the majority of this bridge was filled by current investors, we’re thrilled to welcome a few new folks onto our cap table.
News
The Maryland Stem Cell Research Commission Awards Nanochon Grant Funding
The Maryland Stem Cell Research Commission, the body overseeing The Maryland Stem Cell Research Fund (MSCRF), has awarded Nanochon grant